Source data
Opella transaction milestones, ownership and accounting figures
Sources checked
- 21 October 2024Exclusive negotiations announced
Approximately €16 billion enterprise value Source 1
- 18 February 2025Share purchase agreement signed
Date identified in Sanofi's annual report Source 3
- 30 April 2025Transaction closes
CD&R 50.0%, Sanofi 48.2%, Bpifrance 1.8% Source 2
- 30 April 2025Retained interest first recognised
€3.2 billion accounting value including capitalised transaction costs Source 3
- 2025 annual filingNet cash inflow reported
€10.4 billion cash inflow and €2.6 billion net accounting gain Source 3
The cash inflow and value of the retained interest were reported in separate accounts.
Opella transaction milestones, ownership and accounting figures
The approximate enterprise value, reported net cash inflow and accounting value of the retained stake are different measures.
| Source | |||
|---|---|---|---|
| 21 October 2024 | Exclusive negotiations announced | Approximately €16 billion enterprise value | Source 1 |
| 18 February 2025 | Share purchase agreement signed | Date identified in Sanofi's annual report | Source 3 |
| 30 April 2025 | Transaction closes | CD&R 50.0%, Sanofi 48.2%, Bpifrance 1.8% | Source 2 |
| 30 April 2025 | Retained interest first recognised | €3.2 billion accounting value including capitalised transaction costs | Source 3 |
| 2025 annual filing | Net cash inflow reported | €10.4 billion cash inflow and €2.6 billion net accounting gain | Source 3 |